SUMMARY Plasma methionine enkephalin is increased in liver disease and may contribute to some of the clinical manifestations of hepatic failure. To determine if another 'small' opioid peptide is increased in the plasma of patients with liver disease, leucine enkephalin was measured by radioimmunoassay. Its plasma concentration was raised approximately five-fold in patients with acute liver disease (median 1490 pmol/, range 830-2420) and three-fold in patients with cirrhosis with ascites (960 pmolIl, 470-2900), compared with disease controls (325 pmol/l, 180-740) and healthy controls (305 pmol/l, 180-560). The increase in plasma leucine enkephalin was proportional to the degree of liver damage, as judged in the patients with acute liver disease by its correlation with the prothrombin time (r=0.691, p<O01) and alanine aminotransferase (r=0.502, p<005), and in the patients with cirrhosis by its negative correlation with the plasma albumin (r=-0 743, p<0001). It is unclear whether the raised plasma leucine enkephalin in liver disease is a consequence of diminished hepatic inactivation, increased secretion from sympathetic nerves and adrenal glands, or both.
The liver may play a major role in the elimination of blood borne opioid peptides of octapeptide size or less.' In favour of this hypothesis, the pentapeptide methionine enkephalin'2 but not the much larger opioid peptide, 3-endorphin,' is increased in liver disease. Raised plasma levels of some opioid peptides may contribute to some of the clinical manifestations of hepatic failure. This possibility is indicated by the recent finding that administration of an opioid antagonist, nalmefene, to patients with primary biliary cirrhosis produced an opioid withdrawal reaction, alleviated their pruritus and fatigue, and reduced their plasma bilirubin. 4 Five other opioid peptides comprising eight or fewer amino acids are known (methionine enkephalin-arg-phe, methionine enkephalin-arg-gly-leu, leucine enkephalin, adrenorphin and dynorphin [1] [2] [3] [4] [5] [6] [7] [8] . If the hypothesis of predominant hepatic elimination of these peptides is correct, they may be found to be raised in the plasma of patients with liver disease. Therefore, we have investigated whether this is the case for one such peptide, leucine enkephalin (tyrgly-gly-phe-leu). Venous, non-fasting, blood samples were collected from the resting subjects into chilled citric acid containing bottles.2 Leucine enkephalin was measured by radioimmunoassay, using antibody, tracer and reagents purchased from Immuno Nuclear Corporation, Stillwater, Minnesota, USA. The assay procedure and its validation, including high performance liquid chromatography, were identical to that previously described for methionine enkephalin.2
Within and between assay coefficients of variation were 6% and 8%. Recovery rate was 79%. Minimum sensitivity was 180 pmol/l. Non-specific binding ranged from 3.6-4.7%. Cross-reactivity of the antibody was: dynorphin 1-8 6%, gly-gly-phe-leu 4%, methionine enkephalin 2%, methionine enkephalinarg-phe, methionine enkephalin-arg-gly-leu, dynorphin 1-17, peptide E, peptide F and ,-endorphin all <0-01%.
Data are expressed as medians with ranges. To convert leucine enkephalin values to pg/ml, multiply by 0.556. The statistical significance of differences was determined by the Mann-Whitney U test.
Results
Plasma leucine enkephalin was considerably raised in all the patients with acute liver disease (median 1490 pmol/l, range 830-2420) and in the majority of those with cirrhosis and ascites (960, 470-2900) compared with those with cirrhosis without ascites (415, 180-620), the disease controls (325, 180-740) and the healthy controls (305, 180-560) (Figure) . The peptide's level was slightly increased in the patients with renal failure (560, 180-1020) versus the two groups of controls.
In the acute liver disease patients, plasma leucine enkephalin correlated with the prothrombin time (r=0.691, p<0-01) and the alanine aminotransferase (r=0.502, p<0.05) measured in aliquots of the same blood sample. In the patients with cirrhosis (groups ii and iii combined) the peptide's level was negatively correlated with plasma albumin (r=-0-743, p<0-001) but not with the bilirubin, alanine aminotransferase or alkaline phosphatase. It did not correlate significantly with the plasma creatinine in any of the groups with hepatic or renal failure.
Biochemical data regarding the six groups of subjects are shown in the Table. Discussion This study shows that leucine enkephalin is considerably increased in the plasma of patients with cirrhosis, with ascites, and in patients with acute liver disease. The increase is roughly proportional to the degree of liver damage, as judged in the patients with acute liver disease, by the correlation of the peptide's concentration with the alanine aminotransferase and prothrombin time and in the patients with cirrhosis, by the correlation with the plasma albumin. These findings cannot be explained as a non-specific response to illness, as the disease control subjects, some of whom were very ill, had normal plasma levels of the peptide. It seems unlikely that the raised plasma leucine enkephalin in the patients with liver disease is a consequence of leakage from damaged hepatocytes because these cells are a poor source of enkephalins.' Furthermore, we found considerably increased plasma levels of the peptide in some of the patients with cirrhosis, many of whom had only The data do not permit a conclusion as to whether the increased plasma leucine enkephalin is a consequence of diminished hepatic inactivation, increased secretion, or both. Leucine enkephalin is degraded rapidly by a variety of enzymes,';'6 and the liver contains a high concentration of at least one of these enzymes, leucine aminopeptidase. '7 '8 
